(精编)【医学英文课件】 Nuovi pathways nuovi farmaci quali prospettive教学课件.pptVIP

Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Nuovi pathways nuovi farmaci: quali prospettive? Applicability Company (1) Advisory role Yes AstraZeneca, Bayer, Celgene, Lilly, Novartis, Pfizer, Roche 　 (2) Stock ownership/profit　 None 　 (3) Patent royalties/licensing fees　 None 　 (4) Lecture fees Yes AstraZeneca, Eisai, Genomic Health, Novartis, Pfizer, Pierre Fabre, Roche (5) Manuscript fees None 　 (6) Scholarship fund None 　 (7) Other remuneration None 　 Conflict of Interest Disclosure Focus on ER+